The New Cycle of Weight Fluctuation with Obesity Medications

The introduction of modern treatments such as Wegovy and Mounjaro has transformed the clinical landscape for people living with obesity. These obesity medications, often classified as GLP-1 agonists, simulate hormones that signal satiety to the brain, helping to manage caloric intake.

Despite the initial enthusiasm, researchers are beginning to question what happens when the use of these substances is stopped. Scientific data indicates that cessation of treatment tends to result in the resumption of lost weight and the return of metabolic markers to levels prior to the start of therapy.

The biological impact of interruption

These drugs work, in large part, by silencing the so-called food noise, which encompasses intrusive thoughts and recurring food cravings. When the individual stops taking the medication, the biological effect gradually disappears and hunger returns with intensity.

Without chemical support for the appetite control, it becomes biologically more difficult to maintain the necessary calorie deficit. If the person returns to their pre-treatment eating patterns, weight gain becomes an almost inevitable consequence.

A new format for the accordion effect

Historically, medicine has warned of the risks of the concertina effect caused by restrictive and ineffective diets. Now, experts are observing the emergence of a pharmaceutical version of this cycle, where the patient loses weight, stops using it for reasons of cost or side effects and, later, seeks to resume the prescription.

This cycle of interruption and restart generates metabolic instability and raises questions about the sustainability of the treatment. Exclusive dependence on the drug, without a long-term support plan, can transform medication use into a routine of prescriptive back and forth.

Obesity as a chronic condition

It is essential to treat obesity as a complex and chronic condition, influenced by biological, social and environmental factors. Medication should be seen as a window of opportunity to implement a behavior change effective, and not as an isolated magical solution.

During the period in which hunger is controlled, the patient has the chance to consolidate healthy habits, such as:

• Establish a regular meal routine.
• Integrate physical activity into your daily life.
• Develop practical strategies to manage food triggers.

Success in managing the chronic obesity depends on a multidisciplinary approach. Although medications facilitate weight loss, they do not automatically change the external circumstances and environment in which the patient lives.

Challenges for public health

The growing demand for GLP-1 treatments puts pressure on healthcare systems and raises regulatory concerns. Health authorities emphasize that these substances should not be used for aesthetic purposes by people who do not meet strict medical criteria.

The focus of contemporary medicine must shift to the ongoing support needed when drug treatment is terminated. If weight maintenance depends solely on appetite suppression, the challenge of avoiding weight regain will remain a significant barrier to public health.

Frequently Asked Questions

Why does the weight come back after stopping the medication The medicine reduces appetite; When you suspend use, hunger and cravings return, facilitating caloric consumption that exceeds energy expenditure.

The medicated concertina effect is dangerous Repeated weight fluctuation can impact metabolic and cardiac markers, presenting a clinical challenge for maintaining long-term health.

Medication replaces changing habits No. Experts recommend using it as a support to create routines, and not as an isolated solution that does not require care with diet and physical exercise.

Also read: Fires in Canada: smoke reaches the USA and affects air quality.

Source and methodology

This article was prepared based on information published by refractor.io, on July 16, 2026. See the publicação original: Yo-yo dieting takes on a new shape in the age of Ozempic. HTechBD reorganized and contextualized the data for the Brazilian public, without reproducing the source text.

Image: Nataliya Vaitkevich no Pexels.